Amgen Q1 FY25: where the revenue came from and where it went
The whole income statement of Amgen for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2025
- Reported
- May 2, 2025
Revenue$8.15B
+9% year over year
Gross profit$5.18B
64% margin
Operating profit$1.18B
14% margin
Net profit$1.73B
21% margin
Net profit is larger than what operations earned, because the statement adds $0.80B below it, under Other income, net.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 8.15 | 100% | +9% |
| Other revenue | 2.79 | 34% | |
| Other products | 1.65 | 20% | +20% |
| Prolia | 1.10 | 14% | +10% |
| Repatha (evolocumab) | 0.66 | 8% | +27% |
| Xgeva | 0.57 | 7% | +1% |
| Enbrel | 0.51 | 6% | −10% |
| Evenity | 0.44 | 6% | +29% |
| Otezla | 0.44 | 5% | +11% |
| Cost of revenue | −2.97 | 36% | |
| Gross profit | 5.18 | 64% margin | +7pp |
| SG&A | −1.69 | 21% | −4pp |
| Other | −2.32 | 28% | +0pp |
| Operating profit | 1.18 | 14% margin | +1pp |
| Other income, net | 0.80 | ||
| Tax | −0.24 | ||
| Net profit | 1.73 | 21% margin | +23pp |
107 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest